🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I'm excited to announce Arda Therapeutics! Arda Therapeutics is taking aim at chronic diseases and aging by eliminating the pathological cells that drive these conditions. We recently closed our seed round led by a16z and we are hiring! Read more: ardatx.notion.site/Arda-Therapeut…

Arda's team is expanding! We've opened two new computational roles: a computational biologist and a data engineer. Bring your single cell analysis chops and help us make drugs that target cells, not pathways. ardatx.notion.site/ardatx/Job-Boa….

Arda is delighted to welcome Martin Preyer to the team as our Vice President, Biologics! Martin is an antibody engineering expert and will oversee the generation, characterization, and optimization of novel therapeutics that target and eliminate pathogenic cell populations.

Arda Therapeutics's founder, @afreund83 recently talked with The Bioinformatics CRO's T Grant Belgard 🧬💻 about Arda's strategy of eliminating pathogenic cells to treat chronic diseases, our vision of extending healthy lifespan, and some of the battle scars that come from building a biotech startup.

2023 is off to a great start. We're continuing to move the science of pathogenic cell elimination forward, and we've added three new team members: welcome Nona Ehyaei, Asmiti Sura, and Jack Wang!

Our founder and CEO, @afreund83, will discuss pathogenic cell elimination on April 27th at IndieBio in SF. Come and participate in the conversation!

If you want to know where you are going, it can help to turn around and see where you have been. On June 30, Arda CEO @afreund83 will be chatting with colleagues James Peyer Kristen Fortney about the history of the longevity biotech industry and how we got to where we are today.

The new Arda website is live at ardatx.com. Check it out to learn about our science, our incredible team, and more!

Today at Norn Group’s inaugural “Pathways to Impact” event, BioAge CEO Kristen Fortney joined forces with fellow longevity leaders James Peyer (Cambrian) & Adam Freund (Arda Therapeutics) to share perspectives on how aging biology has evolved, where we are today—and where we’re heading.

A great opportunity for a scientist with biotech/pharma industry experience to contribute individually, lead projects, mentor colleagues, and grow their career. Come build with us! linkedin.com/jobs/view/3680…

Arda CEO Adam Freund will be speaking at Longevity Global's Summit Dec. 5-6th at the Buck Institute for Research on Aging. Learn more and register at longevitygl.org/longevity-summ…."

We're thrilled to announce that Scott Turner (Scott Turner) has joined us as Arda's new Chief Scientific Officer! Scott brings a wealth of experience and expertise in the development and translation of anti-fibrotic therapies from his former role as CSO at Pliant Therapeutics. Welcome!

Arda is pleased to announce the closing of our $43M Series A financing to accelerate the development of precision cell-depleting biologics to treat chronic diseases! The new capital will be used to drive our existing I&I pipeline toward the clinic, expand into new indications,

Thanks to our new investors at Two Sigma Ventures for this excellent write-up. We are excited to work with you!

Arda’s founders, CEO Adam Freund and CTO Rémi Laberge, joined the Translating Aging to explore Arda's cutting-edge approach to treating chronic diseases. Adam and Remi discussed Arda’s origin and shared how the company's single-cell-based discovery platform pinpoints pathogenic